We formally demonstrated that IKKα or BRAF inhibition (by precluding DNA damage repair) synergistically enhance the therapeutic potential of the standard of care therapy in CRC (5-FU plus irinotecan), leading to the eradication of chemotherapy-resistant metastatic human tumors in vivo. Here, BRAF is linked to colorectal carcinoma.